eFFECTOR Therapeutics, Inc.

Locust Walk Acquisition Corp. (Nasdaq: LWAC), a blank-check company sponsored by Locust Walk and focused on the life sciences and healthcare sector, completed its business combination with eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company developing small-molecule therapies that target the eIF4F translation initiation complex for oncology indications. The SPAC raised its initial public offering in 2020 on Nasdaq. Following the close of the de-SPAC transaction, the combined entity operating under the eFFECTOR Therapeutics name filed a Form 10-Q with the SEC on August 12, 2021, accession number 0001193125-21-244053. Sign up at SpacDesk for full filing history, deal analytics, and real-time data on LWAC and hundreds of other SPAC transactions.